Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated logoVertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VRTX
  • CUSIP: 92532F10
  • Web: www.vrtx.com
Capitalization:
  • Market Cap: $38.3372 billion
  • Outstanding Shares: 252,118,000
Average Prices:
  • 50 Day Moving Avg: $154.59
  • 200 Day Moving Avg: $128.57
  • 52 Week Range: $71.46 - $167.85
P/E:
  • Trailing P/E Ratio: 145.30
  • Foreward P/E Ratio: 77.57
  • P/E Growth: 1.38
Sales & Book Value:
  • Annual Revenue: $2.13 billion
  • Price / Sales: 17.90
  • Book Value: $6.66 per share
  • Price / Book: 22.71
Profitability:
  • EBIDTA: $408.78 million
  • Net Margins: 12.05%
  • Return on Equity: 4.64%
  • Return on Assets: 2.41%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 3.49%
  • Quick Ratio: 3.34%
Misc:
  • Average Volume: 1.87 million shs.
  • Beta: 1.75
  • Short Ratio: 1.32
 

Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals Incorporated's earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Wednesday, July, 26th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.33. The firm earned $544.10 million during the quarter, compared to analysts' expectations of $489.95 million. Vertex Pharmaceuticals Incorporated had a return on equity of 4.64% and a net margin of 12.05%. The firm's revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the business posted $0.24 earnings per share. View Vertex Pharmaceuticals Incorporated's Earnings History.

When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Vertex Pharmaceuticals Incorporated.

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

24 equities research analysts have issued 12 month target prices for Vertex Pharmaceuticals Incorporated's shares. Their predictions range from $81.00 to $200.00. On average, they expect Vertex Pharmaceuticals Incorporated's share price to reach $162.96 in the next twelve months. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.

What are analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

  • 1. According to Zacks Investment Research, "Vertex beat estimates for both earnings and sales in Q2 as sales of both its cystic fibrosis (CF) drugs rose. Vertex has two CF drugs in its portfolio with blockbuster potential – Kalydeco & Orkambi. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase patient population and boost sales. Vertex’s CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on the triple combination CF regimens, which are crucial for long-term growth as they have the potential to treat up to 90% of CF patients. We are encouraged by the recent positive data from three of the triple combination regimens. The stock has also shot up this year. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Orkambi’s EU reimbursement remains a key for sales growth in 2H17." (8/4/2017)
  • 2. Cowen and Company analysts commented, "Vertex announced that the FDA has approved Kalydeco for use in CF patients over the." (8/1/2017)
  • 3. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)
  • 4. Maxim Group analysts commented, "Vertex reported 1Q17 with total CF revenue of $481M, which was above consensus of $444M, driven by both Orkambi and Kalydeco revenues beating estimates." (4/28/2017)

Who are some of Vertex Pharmaceuticals Incorporated's key competitors?

Who are Vertex Pharmaceuticals Incorporated's key executives?

Vertex Pharmaceuticals Incorporated's management team includes the folowing people:

  • Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Ian F. Smith CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President
  • Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer
  • David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer
  • Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer
  • Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
  • Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
  • Paul M. Silva, Senior Vice President, Corporate Controller
  • Bruce I. Sachs, Lead Director, Independent Director
  • Elaine S. Ullian, Co-Lead Independent Director

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.70%), FMR LLC (7.33%), Vanguard Group Inc. (6.73%), Capital World Investors (6.11%), State Street Corp (4.51%) and JPMorgan Chase & Co. (3.32%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Ameriprise Financial Inc., JPMorgan Chase & Co., State Street Corp, HealthCor Management L.P., FMR LLC, Lazard Asset Management LLC and Laurion Capital Management LP. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Old Mutual Global Investors UK Ltd., AJO LP, Vanguard Group Inc., TIAA CREF Investment Management LLC, Fred Alger Management Inc., Janus Henderson Group PLC and Columbus Circle Investors. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals Incorporated's stock price today?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $151.26.


MarketBeat Community Rating for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  965 (Vote Outperform)
Underperform Votes:  525 (Vote Underperform)
Total Votes:  1,490
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 21 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $162.96 (7.73% upside)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Needham & Company LLCReiterated RatingBuy$195.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$175.00LowView Rating Details
8/22/2017Jefferies Group LLCReiterated RatingBuyHighView Rating Details
8/1/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
8/1/2017ArgusBoost Price TargetBuy$71.46 -> $175.00LowView Rating Details
7/27/2017BMO Capital MarketsReiterated RatingOutperform$180.00 -> $182.00LowView Rating Details
7/27/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$150.00 -> $175.00MediumView Rating Details
7/27/2017J P Morgan Chase & CoSet Price TargetBuy$175.00 -> $184.00HighView Rating Details
7/27/2017Maxim GroupSet Price TargetBuy$195.00HighView Rating Details
7/22/2017Morgan StanleyReiterated RatingOverweight$153.00 -> $190.00LowView Rating Details
7/21/2017Robert W. BairdReiterated RatingOutperform$136.00 -> $171.00LowView Rating Details
7/21/2017Citigroup Inc.Reiterated RatingBuy$135.00 -> $190.00LowView Rating Details
7/19/2017Credit Suisse GroupBoost Price TargetOutperform$125.00 -> $195.00HighView Rating Details
7/19/2017JMP SecuritiesReiterated RatingOutperformHighView Rating Details
7/19/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$181.00HighView Rating Details
7/19/2017Piper Jaffray CompaniesBoost Price TargetOverweight$194.00HighView Rating Details
7/19/2017HC WainwrightReiterated RatingHold$85.00HighView Rating Details
7/19/2017Janney Montgomery ScottUpgradeNeutral -> Buy$98.00HighView Rating Details
7/19/2017Barclays PLCUpgradeEqual Weight -> Overweight$115.00 -> $180.00HighView Rating Details
7/18/2017Stifel NicolausBoost Price TargetBuy -> Buy$130.00 -> $154.00HighView Rating Details
6/22/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
6/2/2017CIBCUpgradeMarket Perform -> OutperformLowView Rating Details
5/19/2017Bank of America CorporationReiterated RatingNeutral$121.00 -> $125.00LowView Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00N/AView Rating Details
4/28/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$109.00 -> $88.00N/AView Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/23/2017$0.40N/AView Earnings Details
7/26/2017Q2 2017$0.06$0.39$489.95 million$544.10 millionViewN/AView Earnings Details
4/27/2017Q1 2017$0.04$0.13$692.64 million$714.72 millionViewN/AView Earnings Details
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
2017 EPS Consensus Estimate: $0.56
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.02)$0.04$0.02
Q2 20174$0.02$0.11$0.07
Q3 20173$0.07$0.11$0.09
Q4 20173$0.26$0.56$0.38
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/29/2013quarterly$0.402/20/20133/13/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 92.85%
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017David AltshulerEVPSell1,796$160.00$287,360.00View SEC Filing  
8/7/2017Ian F SmithCFOSell4,250$155.39$660,407.50View SEC Filing  
8/7/2017Paul M SilvaSVPSell1,289$152.88$197,062.32View SEC Filing  
8/3/2017Jeffrey ChodakewitzCMOSell5,390$154.17$830,976.30View SEC Filing  
8/3/2017Michael PariniEVPSell2,330$155.72$362,827.60View SEC Filing  
8/2/2017Ian F SmithCFOSell2,155$154.17$332,236.35View SEC Filing  
8/2/2017Jeffrey ChodakewitzCMOSell1,796$154.13$276,817.48View SEC Filing  
8/2/2017Paul M SilvaSVPSell1,289$151.80$195,670.20View SEC Filing  
7/31/2017Jeffrey M LeidenCEOSell11,063$152.81$1,690,537.03View SEC Filing  
7/31/2017Paul M SilvaSVPSell860$152.99$131,571.40View SEC Filing  
7/31/2017Stuart A ArbuckleEVPSell2,125$152.99$325,103.75View SEC Filing  
7/21/2017Amit SachdevEVPSell28,625$160.93$4,606,621.25View SEC Filing  
7/21/2017Ian F SmithCFOSell133,750$160.98$21,531,075.00View SEC Filing  
7/21/2017Jeffrey ChodakewitzCMOSell46,733$160.96$7,522,143.68View SEC Filing  
7/21/2017Jeffrey M LeidenCEOSell216,624$160.96$34,867,799.04View SEC Filing  
7/21/2017Paul M SilvaSVPSell43,443$161.07$6,997,364.01View SEC Filing  
7/19/2017Michael PariniEVPSell10,829$161.00$1,743,469.00View SEC Filing  
7/17/2017Jeffrey ChodakewitzCMOSell573$129.85$74,404.05View SEC Filing  
7/3/2017Jeffrey ChodakewitzCMOSell3,438$127.80$439,376.40View SEC Filing  
6/21/2017Jeffrey ChodakewitzCMOSell5,157$132.87$685,210.59View SEC Filing  
6/21/2017Paul M SilvaSVPSell2,577$133.36$343,668.72View SEC Filing  
6/5/2017David AltshulerEVPSell7,500$130.00$975,000.00View SEC Filing  
6/2/2017Jeffrey M LeidenCEOSell147,101$129.50$19,049,579.50View SEC Filing  
6/2/2017Sangeeta N BhatiaDirectorSell1,176$128.44$151,045.44View SEC Filing  
6/2/2017Stuart A ArbuckleEVPSell70,969$128.06$9,088,290.14View SEC Filing  
5/2/2017Jeffrey ChodakewitzCMOSell8,979$121.05$1,086,907.95View SEC Filing  
4/28/2017Jeffrey M LeidenCEOSell157,200$119.50$18,785,400.00View SEC Filing  
4/5/2017Jeffrey ChodakewitzCMOSell8,021$114.00$914,394.00View SEC Filing  
4/3/2017Jeffrey ChodakewitzCMOSell2,291$108.85$249,375.35View SEC Filing  
3/29/2017Amit SachdevEVPSell80,500$107.63$8,664,215.00View SEC Filing  
3/29/2017Jeffrey ChodakewitzCMOSell13,750$106.65$1,466,437.50View SEC Filing  
3/29/2017Paul M SilvaSVPSell1,688$106.30$179,434.40View SEC Filing  
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.76View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.39View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.00View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.84View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.25View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.00View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.00View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.00View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.00View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.00View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.00View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.00View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.00View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.72View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.84View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.00View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.91View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.00View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.90View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Source:
DateHeadline
finance.yahoo.com logoVertex's Rocky September Causes Vetr To Urge Sell
finance.yahoo.com - September 23 at 10:53 AM
finance.yahoo.com logoVertex to Present at the Leerink Partners Roundtable Series on September 27
finance.yahoo.com - September 23 at 10:53 AM
finance.yahoo.com logoVertex Pharmaceuticals: Going From 'Crisis' To Blockbuster
finance.yahoo.com - September 23 at 10:53 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Downgraded to "Sell" at Vetr Inc.
www.americanbankingnews.com - September 21 at 7:35 PM
finance.yahoo.com logoVertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference
finance.yahoo.com - September 19 at 3:27 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard
finance.yahoo.com - September 19 at 9:26 AM
americanbankingnews.com logoNeedham & Company LLC Reaffirms Buy Rating for Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - September 17 at 8:58 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Earns Outperform Rating from Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM
marketwatch.com logoDeep Dive: Analysts have raised, or lowered, their price targets the most on these U.S. stocks
www.marketwatch.com - September 14 at 7:32 AM
finance.yahoo.com logoAnalysts have raised, or lowered, their price targets the most on these U.S. stocks
finance.yahoo.com - September 12 at 12:01 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Expected to Post Quarterly Sales of $512.50 Million
www.americanbankingnews.com - September 12 at 11:36 AM
fool.com logo2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term
www.fool.com - September 12 at 8:18 AM
americanbankingnews.com logo Brokerages Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Earnings of $0.35 Per Share
www.americanbankingnews.com - September 10 at 2:40 PM
finance.yahoo.com logoVertex to Present at the Morgan Stanley Healthcare Conference on September 11
finance.yahoo.com - September 8 at 10:06 AM
finance.yahoo.com logoVertex Pharmaceuticals Could Be Headed Higher Once Again
finance.yahoo.com - September 7 at 11:00 AM
finance.yahoo.com logoTop Biotech Stock Near Buy Zone After FDA Drug Approval
finance.yahoo.com - September 7 at 11:00 AM
streetinsider.com logoVertex Pharma (VRTX) Names Ironwood (IRWD) CFO Tom Graney as its New CFO - StreetInsider.com
www.streetinsider.com - September 6 at 10:05 AM
finance.yahoo.com logoBehind Bioverativ’s Analyst Recommendations This September
finance.yahoo.com - September 6 at 10:05 AM
finance.yahoo.com logoVertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer
finance.yahoo.com - September 6 at 10:05 AM
finance.yahoo.com logoVertex Pharma surges 1% after news of new CFO
finance.yahoo.com - September 6 at 10:05 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) EVP Sells $287,360.00 in Stock
www.americanbankingnews.com - September 5 at 8:06 PM
fool.com logo3 Growth Stocks for the 21st Century
www.fool.com - September 5 at 3:59 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 5 at 8:54 AM
finance.yahoo.com logo4 Biotech Stocks That More Than Doubled This Year
finance.yahoo.com - September 2 at 10:19 AM
finance.yahoo.com logoHow Vertex Pharmaceuticals Performed in 2Q17
finance.yahoo.com - September 1 at 10:55 AM
finance.yahoo.com logoVertex Saw Successful Results from VX-440 Phase 2 Study
finance.yahoo.com - September 1 at 10:55 AM
finance.yahoo.com logoVertex Presented Successful Results for Cystic Fibrosis Treatment
finance.yahoo.com - September 1 at 10:55 AM
finance.yahoo.com logoHow Are Orkambi and Kalydeco Positioned after 2Q17?
finance.yahoo.com - September 1 at 10:55 AM
investorplace.com logoVRTX Stock: 3 Reasons to Be Cautious on Vertex Pharmaceuticals ... - Investorplace.com
investorplace.com - August 30 at 8:53 PM
seekingalpha.com logoVertex Combo Treatments Continue To Advance - Seeking Alpha
seekingalpha.com - August 30 at 8:53 PM
finance.yahoo.com logoVertex Pharmaceuticals (VRTX) Down 5.2% Since Earnings Report: Can It Rebound?
finance.yahoo.com - August 30 at 10:57 AM
investorplace.com logo3 Reasons to Be Cautious on Vertex Pharmaceuticals Incorporated (VRTX) Stock
investorplace.com - August 29 at 2:18 PM
investorplace.com logoVertex Pharmaceuticals Incorporated (VRTX) Stock Could Burn Investors - Investorplace.com
investorplace.com - August 29 at 9:31 AM
investorplace.com logoVertex Pharmaceuticals Incorporated (VRTX) Stock Could Burn Investors
investorplace.com - August 29 at 5:15 AM
nasdaq.com logoVertex's Cystic Fibrosis Combo Gets Priority Review in US - Nasdaq
www.nasdaq.com - August 25 at 12:26 PM
streetinsider.com logoVertex Pharma (VRTX) Announces Acceptance of its Applications for Review of Tezacaftor/Ivacaftor Combination ... - StreetInsider.com
www.streetinsider.com - August 25 at 12:26 PM
finance.yahoo.com logoVertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA
finance.yahoo.com - August 25 at 12:26 PM
finance.yahoo.com logoVertex's Cystic Fibrosis Combo Gets Priority Review in U.S.
finance.yahoo.com - August 25 at 12:26 PM
americanbankingnews.com logo$511.72 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter
www.americanbankingnews.com - August 24 at 1:04 AM
finance.yahoo.com logoLab-made "mini organs" helping doctors treat cystic fibrosis
finance.yahoo.com - August 23 at 11:45 PM
nasdaq.com logoCommit To Buy Vertex Pharmaceuticals At $100, Earn 4.5% Using Options
www.nasdaq.com - August 23 at 6:43 PM
nasdaq.com logoMarket Close Report: NASDAQ Composite index closes at 6297.48 up 84.35 points - Nasdaq
www.nasdaq.com - August 23 at 1:41 PM
finance.yahoo.com logoLab-made "mini organs" helping doctors treat cystic fibrosis
finance.yahoo.com - August 23 at 1:41 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Expected to Post Earnings of $0.35 Per Share
www.americanbankingnews.com - August 23 at 12:08 AM
investorplace.com logoVRTX Stock: Vertex Pharmaceuticals Incorporated (VRTX) Stock Is ... - Investorplace.com
investorplace.com - August 22 at 7:46 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - August 19 at 2:44 PM
fool.com logo3 Stocks That Could Put Alibaba's Returns to Shame
www.fool.com - August 16 at 8:28 AM
finance.yahoo.com logoETFs with exposure to Vertex Pharmaceuticals, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 8:47 PM
investorplace.com logoWhy Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn't Worth the Risk - Investorplace.com
investorplace.com - August 15 at 8:07 AM
investorplace.com logoWhy Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk
investorplace.com - August 14 at 11:35 AM

Social

Chart

Vertex Pharmaceuticals Incorporated (VRTX) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff